<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01379547</url>
  </required_header>
  <id_info>
    <org_study_id>201101079RB</org_study_id>
    <nct_id>NCT01379547</nct_id>
  </id_info>
  <brief_title>Procalcitonin to Shorten Antibiotics Duration in ICU Patients</brief_title>
  <acronym>ProShort</acronym>
  <official_title>Procalcitonin to Shorten Antibiotics Duration in ICU Patients- A China, Hong-Kong, Taiwan Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinjiang Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Princess Margaret Hospital, Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is aimed to show that implementation of a procalcitonin-guided antibiotics
      algorithm may result in shortened antibiotics course in ICU sepsis patients without inferior
      outcome as compared to the conventional therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of antibiotic therapy in patients with sepsis is largely empirical. An extended
      treatment course for up to two weeks is a common practice for patients with sepsis in the
      ICU, despite lack of evidence for this duration of therapy.

      Procalcitonin (PCT) is a new biomarker that has high negative predictive value for systemic
      bacterial infection. The purpose of this trial is to evaluate whether serial PCT measurements
      can shorten antibiotic treatment duration in patients with sepsis in the ICU.

      Specific Aims

        1. To show that implementation of a procalcitonin-guided antibiotics stewardship algorithm
           may result in shortened antibiotics course in ICU sepsis patients

        2. To show that implementation of a procalcitonin-guided antibiotics stewardship algorithm
           may not result in inferior outcome as compared to conventional therapy
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average antibiotics duration</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>28-day mortality rate</measure>
    <time_frame>28 days</time_frame>
    <description>Safety endpoints</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of antibiotics use in both arms</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of fever within 72 hours of antibiotics discontinuation</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APACHE-II score or SOFA score</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reinfection between 72-hours and 28 days post antibiotics discontinuation</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day all-cause mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day infection related readmission rate</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1700</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Conventional Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who will be randomized to arm 1 will receive antibiotic therapy with a duration based on conventional practice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>procalcitonin-guided antibiotics treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who will be randomized to arm 2 will receive antibiotics therapy with a duration based on procalcitonin-guided algorithm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Procalcitonin guided antibiotics treatment algorithm</intervention_name>
    <description>Patients who will be randomized to arm 2 will receive antibiotics therapy with a duration based on procalcitonin measurement on day 5, 7 and 9.</description>
    <arm_group_label>procalcitonin-guided antibiotics treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Conventional treatment</intervention_name>
    <description>Patients who will be randomized to arm 1 will receive antibiotic therapy with a duration based on conventional practice.</description>
    <arm_group_label>Conventional Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with laboratory- or image-confirmed severe infection at admission or
             during stay in ICU will be eligible for inclusion.

        Definition of laboratory- or image-confirmed severe infection:

          1. Two or more of four Signs of Inflammation

               -  Temperature &gt; 38.3℃ or &lt; 36℃

               -  Heart rate &gt; 90 beats/min

               -  Respiratory rate &gt; 20 breaths/min or PaCO2 &lt; 32 mmHg

               -  WBC &gt; 12,000 cells/mm3, &lt; 4000 cells/mm3, or &gt; 10% bands

          2. Initial Procalcitonin &gt; 0.5 ng/mL

          3. Presence of either laboratory or image evidence of infection

        Laboratory evidence:

        Sign of inflammation in urine, CSF, ascites, pleural effusion or local abscess

        Image evidence:

        Compatible findings on Chest X ray、ultrasound、CT、or MR image

        Exclusion Criteria:

          -  Age less than 20 years

          -  Known pregnancy

          -  Presence of DNR order

          -  Expected ICU stay less than 3 days

          -  Neutropenia (ANC count &lt; 500/mm3)

          -  Specific infections for which long-term antibiotic treatment is strongly recommended:
             lung abscess or empyema, bacterial meningitis, osteomyelitis, infective endocarditis,
             local abscess, mediastinitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chien-Chang Lee, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chien-Chang Lee, MD, MSc</last_name>
    <phone>+886-972-651951</phone>
    <email>cclee100@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Critical Care Medicine, The First Affiliated Hospital of Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shiangtai Yu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Critical Care Medicine, The 301 People Liberation Army General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Chin Song, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emergency Department, Beijing Chao-Yang Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunsheng Li, MD</last_name>
    </contact>
    <investigator>
      <last_name>Chunsheng Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emergency Department, Ruijin Hospital, Jiaotong University, School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yiming Lu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yiming Lu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emergency Department, Xinhua Hospital, Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shuming Pan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Critical Care Medicine, The General Hospital of Tianjin Medical University</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Min Peng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Pathology, Princess Margaret Hospita</name>
      <address>
        <city>Lai Chi Kok</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bosco Lam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Emergency, National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chien-Chang Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ang Yuan, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hsien-Ho Lin, MD ScD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shan-Chewn Chang, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
    <country>Hong Kong</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2011</study_first_submitted>
  <study_first_submitted_qc>June 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2011</study_first_posted>
  <last_update_submitted>November 26, 2012</last_update_submitted>
  <last_update_submitted_qc>November 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Procalcitonin</keyword>
  <keyword>sepsis</keyword>
  <keyword>ICU</keyword>
  <keyword>antibiotic</keyword>
  <keyword>antibiotic duration</keyword>
  <keyword>Antibiotic treatment duration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Calcitonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

